vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and Tecnoglass Inc. (TGLS). Click either name above to swap in a different company.
ANI PHARMACEUTICALS INC is the larger business by last-quarter revenue ($247.1M vs $245.3M, roughly 1.0× Tecnoglass Inc.). ANI PHARMACEUTICALS INC runs the higher net margin — 11.1% vs 10.6%, a 0.5% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs 2.4%). ANI PHARMACEUTICALS INC produced more free cash flow last quarter ($29.1M vs $11.4M). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs 12.8%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
Tecnoglass Inc. is a leading manufacturer of high-performance architectural glass, aluminum windows, doors, and associated building components. It primarily caters to residential and commercial construction sectors across North America and Latin America, offering custom, energy-efficient solutions for new construction and renovation projects.
ANIP vs TGLS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $245.3M |
| Net Profit | $27.5M | $26.1M |
| Gross Margin | — | 40.0% |
| Operating Margin | 14.1% | 18.3% |
| Net Margin | 11.1% | 10.6% |
| Revenue YoY | 29.6% | 2.4% |
| Net Profit YoY | 367.5% | -44.5% |
| EPS (diluted) | $1.14 | $0.57 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | $245.3M | ||
| Q3 25 | $227.8M | $260.5M | ||
| Q2 25 | $211.4M | $255.5M | ||
| Q1 25 | $197.1M | $222.3M | ||
| Q4 24 | $190.6M | $239.6M | ||
| Q3 24 | $148.3M | $238.3M | ||
| Q2 24 | $138.0M | $219.7M | ||
| Q1 24 | $137.4M | $192.6M |
| Q4 25 | $27.5M | $26.1M | ||
| Q3 25 | $26.6M | $47.2M | ||
| Q2 25 | $8.5M | $44.1M | ||
| Q1 25 | $15.7M | $42.2M | ||
| Q4 24 | $-10.3M | $47.0M | ||
| Q3 24 | $-24.2M | $49.5M | ||
| Q2 24 | $-2.3M | $35.0M | ||
| Q1 24 | $18.2M | $29.7M |
| Q4 25 | — | 40.0% | ||
| Q3 25 | — | 42.7% | ||
| Q2 25 | — | 44.7% | ||
| Q1 25 | — | 43.9% | ||
| Q4 24 | — | 44.5% | ||
| Q3 24 | — | 45.8% | ||
| Q2 24 | — | 40.8% | ||
| Q1 24 | — | 38.8% |
| Q4 25 | 14.1% | 18.3% | ||
| Q3 25 | 15.9% | 25.1% | ||
| Q2 25 | 6.6% | 24.0% | ||
| Q1 25 | 13.3% | 26.7% | ||
| Q4 24 | -2.3% | 28.0% | ||
| Q3 24 | -13.8% | 28.4% | ||
| Q2 24 | 3.7% | 23.3% | ||
| Q1 24 | 14.8% | 21.3% |
| Q4 25 | 11.1% | 10.6% | ||
| Q3 25 | 11.7% | 18.1% | ||
| Q2 25 | 4.0% | 17.3% | ||
| Q1 25 | 8.0% | 19.0% | ||
| Q4 24 | -5.4% | 19.6% | ||
| Q3 24 | -16.3% | 20.8% | ||
| Q2 24 | -1.7% | 15.9% | ||
| Q1 24 | 13.2% | 15.4% |
| Q4 25 | $1.14 | $0.57 | ||
| Q3 25 | $1.13 | $1.01 | ||
| Q2 25 | $0.36 | $0.94 | ||
| Q1 25 | $0.69 | $0.90 | ||
| Q4 24 | $-0.45 | $1.00 | ||
| Q3 24 | $-1.27 | $1.05 | ||
| Q2 24 | $-0.14 | $0.75 | ||
| Q1 24 | $0.82 | $0.63 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $104.1M |
| Total DebtLower is stronger | — | $174.4M |
| Stockholders' EquityBook value | $540.7M | $713.1M |
| Total Assets | $1.4B | $1.3B |
| Debt / EquityLower = less leverage | — | 0.24× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | $104.1M | ||
| Q3 25 | $262.6M | $127.1M | ||
| Q2 25 | $217.8M | $140.9M | ||
| Q1 25 | $149.8M | $160.2M | ||
| Q4 24 | $144.9M | $137.5M | ||
| Q3 24 | $145.0M | $124.8M | ||
| Q2 24 | $240.1M | $129.5M | ||
| Q1 24 | $228.6M | $138.8M |
| Q4 25 | — | $174.4M | ||
| Q3 25 | — | $114.7M | ||
| Q2 25 | — | $110.6M | ||
| Q1 25 | — | $110.6M | ||
| Q4 24 | — | $111.1M | ||
| Q3 24 | — | $126.8M | ||
| Q2 24 | — | $144.7M | ||
| Q1 24 | — | $160.9M |
| Q4 25 | $540.7M | $713.1M | ||
| Q3 25 | $505.8M | $764.0M | ||
| Q2 25 | $436.8M | $736.0M | ||
| Q1 25 | $418.6M | $685.1M | ||
| Q4 24 | $403.7M | $631.2M | ||
| Q3 24 | $405.9M | $613.3M | ||
| Q2 24 | $455.8M | $574.8M | ||
| Q1 24 | $452.0M | $573.6M |
| Q4 25 | $1.4B | $1.3B | ||
| Q3 25 | $1.4B | $1.2B | ||
| Q2 25 | $1.3B | $1.2B | ||
| Q1 25 | $1.3B | $1.1B | ||
| Q4 24 | $1.3B | $1.0B | ||
| Q3 24 | $1.3B | $996.3M | ||
| Q2 24 | $920.8M | $942.5M | ||
| Q1 24 | $914.5M | $981.6M |
| Q4 25 | — | 0.24× | ||
| Q3 25 | — | 0.15× | ||
| Q2 25 | — | 0.15× | ||
| Q1 25 | — | 0.16× | ||
| Q4 24 | — | 0.18× | ||
| Q3 24 | — | 0.21× | ||
| Q2 24 | — | 0.25× | ||
| Q1 24 | — | 0.28× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $31.0M |
| Free Cash FlowOCF − Capex | $29.1M | $11.4M |
| FCF MarginFCF / Revenue | 11.8% | 4.7% |
| Capex IntensityCapex / Revenue | 0.5% | 8.0% |
| Cash ConversionOCF / Net Profit | 1.10× | 1.19× |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | $34.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $31.0M | ||
| Q3 25 | $44.1M | $40.0M | ||
| Q2 25 | $75.8M | $17.9M | ||
| Q1 25 | $35.0M | $46.9M | ||
| Q4 24 | $15.9M | $61.1M | ||
| Q3 24 | $12.5M | $41.5M | ||
| Q2 24 | $17.4M | $34.5M | ||
| Q1 24 | $18.3M | $33.4M |
| Q4 25 | $29.1M | $11.4M | ||
| Q3 25 | $38.0M | $21.2M | ||
| Q2 25 | $71.8M | $-14.7M | ||
| Q1 25 | $32.5M | $16.5M | ||
| Q4 24 | $13.5M | $35.4M | ||
| Q3 24 | $7.7M | $17.8M | ||
| Q2 24 | $13.0M | $14.2M | ||
| Q1 24 | $13.7M | $23.6M |
| Q4 25 | 11.8% | 4.7% | ||
| Q3 25 | 16.7% | 8.2% | ||
| Q2 25 | 34.0% | -5.7% | ||
| Q1 25 | 16.5% | 7.4% | ||
| Q4 24 | 7.1% | 14.8% | ||
| Q3 24 | 5.2% | 7.5% | ||
| Q2 24 | 9.4% | 6.5% | ||
| Q1 24 | 10.0% | 12.2% |
| Q4 25 | 0.5% | 8.0% | ||
| Q3 25 | 2.7% | 7.2% | ||
| Q2 25 | 1.9% | 12.7% | ||
| Q1 25 | 1.3% | 13.7% | ||
| Q4 24 | 1.3% | 10.7% | ||
| Q3 24 | 3.2% | 9.9% | ||
| Q2 24 | 3.2% | 9.2% | ||
| Q1 24 | 3.3% | 5.1% |
| Q4 25 | 1.10× | 1.19× | ||
| Q3 25 | 1.66× | 0.85× | ||
| Q2 25 | 8.87× | 0.41× | ||
| Q1 25 | 2.23× | 1.11× | ||
| Q4 24 | — | 1.30× | ||
| Q3 24 | — | 0.84× | ||
| Q2 24 | — | 0.98× | ||
| Q1 24 | 1.00× | 1.13× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
TGLS
| Product Sales | $164.2M | 67% |
| Fixed Price Contracts | $81.1M | 33% |
| Related Party | $692.0K | 0% |
